{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 82,
  "pageCount": 366,
  "prevPage": 81,
  "nextPage": 83,
  "slideType": "preempt_rebuttal",
  "function": "preempt_rebuttal",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a 'villain critique' style to undermine the target drug (pitolisant) by associating it with failed industry-wide efforts.",
  "elementsJson": [
    "paragraph",
    "quote_block"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/82",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-82",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "All three were intimately familiar with pitolisant and criticized it for having the same fatal flaws, based on their analysis or testing, and characterized it as an old, simple, and inferior compound compared to the molecules they developed - and which still failed.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9ccf-68d022a233d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.86,
        "x": 0.07,
        "y": 0.55
      },
      "kind": "paragraph",
      "text": "We begin with color by an ex-executive/senior scientist at Abbott, now at another major pharma company, who stated that they had an extensive H3 development program that \"never went anywhere\" - specifically for narcolepsy - despite their decades-long experience with histamine receptors given Abbott's H1 agonist drug betahistine.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0edc75c4-f667-413e-aaf9-02cc7fb5f29c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.86,
        "x": 0.07,
        "y": 0.19
      },
      "kind": "paragraph",
      "text": "In two cases, they appear to have independently synthesized and studied pitolisant as a comparator. Despite years of effort, all three companies faced insurmountable challenges, such as bioavailability, drug variability/instability, blood-brain penetration, and toxicity, leading to the failure of their respective programs.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b751d2f-a4d0-4e41-a4d4-121c5bc7d482",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "We then consulted senior scientists from three major pharma companies - Abbott, Johnson & Johnson/Janssen, and GSK - who worked on similar H3 receptor antagonist/inverse agonist drug development projects.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8253770c-a770-48e1-a260-0d13e5524f78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.86,
        "x": 0.07,
        "y": 0.37
      },
      "kind": "paragraph",
      "text": "The scientists provided detailed, consistent, and devastating evidence, describing the issues as unsolvable and inherent to this class of drugs. All three were intimately familiar with pitolisant and criticized it for having the same fatal flaws, based on their analysis or testing, and characterized it as an old, simple, and inferior compound compared to the molecules they developed - and which still failed.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9753eb08-0353-4f3f-b4f6-851bb39265fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.68
      },
      "kind": "quote",
      "text": "Abbott had an extensive H3 receptor program that \"never went anywhere\" - specifically for narcolepsy\nA: \"At Abbott, we had historically worked a lot on a histaminic receptor...\"\nQ: \"And did it ever go anywhere?\"\nA: \"No, it never went anywhere.\"",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f163f94d-7bac-46a6-aa07-020d7307080b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"No, it never went anywhere.\" — Senior pharmaceutical executive/scientist, previously at Abbott and now at another major pharma company",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9ccf-6d7963e0145d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18ce4f6c-efae-49f0-86bd-059584947b8e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "villain-critique",
      "slug": null,
      "matchId": "191a61b9-9c21-4729-9072-b73e1e0d710a",
      "evidence": "The slide characterizes the target drug as 'old, simple, and inferior' and cites failed industry attempts to discredit it.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}